Compare HMR & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMR | ICCC |
|---|---|---|
| Founded | 1984 | 1982 |
| Country | Greece | United States |
| Employees | 52 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 75.8M |
| IPO Year | N/A | 1995 |
| Metric | HMR | ICCC |
|---|---|---|
| Price | $1.19 | $9.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 384.4K | 20.6K |
| Earning Date | 06-09-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | $64.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $44.67 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.73 | $4.52 |
| 52 Week High | $2.10 | $10.75 |
| Indicator | HMR | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 46.62 |
| Support Level | $1.11 | $5.72 |
| Resistance Level | $1.29 | $10.75 |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 5.61 | 0.00 |
Heidmar Maritime Holdings Corp is a commercial and technical management company that operates tanker and dry-bulk vessel pools. The group, along with its subsidiaries, operates as a growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. Its lines of business currently include asset management, tanker pooling, commercial and time charters, assisting clients with the buying and selling of ships, and technical management services for individual vessels, which include assistance in technical operations and crewing of the vessel. Its geographic areas are Singapore, the USA, the Marshall Islands, the United Arab Emirates, Germany, Switzerland, and Other.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.